[Essential phospholipids in the treatment of chronic pyelonephritis].
The author's investigations led them to the conclusion that clinical manifestation of chronic pyelonephritis is associated with destabilization of lipid bilayer of red cell membranes, renal tissue, activation of lipid peroxidation (LPO), rising lipid and LPO products excretion with the urine. 31 patients with chronic pyelonephritis received combined therapy comprising essential phospholipids. 25 control patients with the same disease were not given essentiale-forte. Finally, the latter had longer fever duration, more active inflammation. The former had also low urine excretion of oxalates and normal lipid composition of biological membranes.
Ovchinnikov
A A
AA
Tsvettsikh
V E
VE
Berdichevskiĭ
B A
BA
Lykov
V N
VN
Suktanbaev
V R
VR
Murychev
A V
AV
D000293:Adolescent; D000328:Adult; D002908:Chronic Disease; D004341:Drug Evaluation; D004910:Erythrocyte Membrane / Q000187:drug effects / Q000378:metabolism; D005260:Female; D006801:Humans; D015227:Lipid Peroxidation / Q000187:drug effects; D008297:Male; D008563:Membrane Lipids / Q000378:metabolism; D008875:Middle Aged; D010713:Phosphatidylcholines / Q000009:adverse effects / Q000627:therapeutic use*; D011704:Pyelonephritis / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism; D014545:Urinary Calculi / Q000175:diagnosis / Q000188:drug therapy / Q000378:metabolism
D008563:Membrane Lipids; D010713:Phosphatidylcholines; C011246:essential 303 forte